Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Solvay Pharmaceuticals
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Histological evidence of non-CNS malignancy (primary or metastatic disease) and lymphomas which are not involving the bone marrow.
Undergoing single or multiple days of chemotherapy as long as Day 1 chemotherapy includes:
1. a moderate-to-high emetogenic regimen, or
2. oxaliplatin at doses employed for treatment of colon cancer, or
3. the combination of AC \[AdriamycinÒ (60 mg/m2) with cyclophosphamide (600 mg/m2)\] as to be used for the chemotherapeutic drug regimen involving taxanes in the treatment of breast cancer.
You may not be if
Chemotherapy agents falling into the low (Level 1), moderate-to-low (Level 2), moderate (Level 3) unless used in combination with a Level 4 chemotherapy agent on Day 1 of the study.
Chemotherapy agents falling into the high (Level 5) classification during study.
Any combination of chemotherapy agents that does not fall into the moderate-to-high (Level 4) classification
Clareo Health | Dronabinol Versus Standard Ondansetron Antiemetic Therapy in Preventing Delayed-Onset Chemotherapy-Induced Nausea and Vomiting
